522 related articles for article (PubMed ID: 28758574)
1. Personalized & Precision Medicine in Cancer: A Theranostic Approach.
Choudhury P; Gupta M
Curr Radiopharm; 2017 Nov; 10(3):166-170. PubMed ID: 28758574
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
4.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
5. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
[TBL] [Abstract][Full Text] [Related]
6. [PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy].
Derlin T; Bengel FM
Pneumologie; 2017 Jan; 71(1):48-62. PubMed ID: 28114710
[No Abstract] [Full Text] [Related]
7. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
8. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.
Sheikhbahaei S; Mena E; Pattanayak P; Taghipour M; Solnes LB; Subramaniam RM
PET Clin; 2017 Jan; 12(1):105-118. PubMed ID: 27863562
[TBL] [Abstract][Full Text] [Related]
10. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
[TBL] [Abstract][Full Text] [Related]
11.
El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
13. An introduction to the clinical practice of theranostics in oncology.
Turner JH
Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054
[TBL] [Abstract][Full Text] [Related]
14. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
15. Nuclear Medicine Imaging Procedures in Oncology.
Mohan AM; Beindorff N; Brenner W
Methods Mol Biol; 2021; 2294():297-323. PubMed ID: 33742410
[TBL] [Abstract][Full Text] [Related]
16. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
17. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].
Werner RA; Bengel FM; Derlin T
Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Acar E; Kaya GÇ
Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
[TBL] [Abstract][Full Text] [Related]
19. [Oncological theranostics in nuclear medicine].
Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
[TBL] [Abstract][Full Text] [Related]
20. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
